|
Bernard
O’Brien Institute of Microsurgery (BOBIM)
Overview
The Bernard O’Brien Institute of Microsurgery (BOBIM) was
established in 1970 with the twin aims of providing expertise in
reconstructive microsurgery and postgraduate training of surgeons
in such techniques. Under Professor Wayne Morrison, the BOBIM has
expanded into the area of basic scientific research and has recruited
high calibre staff in the fields of tissue engineering and cancer
research.
The research activities of the Institute have focussed on the following
areas of investigation:
Tissue engineering: The growing of human tissue
for use in transplantation and surgical reconstruction. This is
the main focus of our research efforts at the Institute and we
are internationally recognised for our achievements.
Inflammation: Our studies aim to discover the
molecular mechanisms underlying macrophage functions since knowledge
of fundamental biological processes will ultimately result in
better treatment of patients following trauma and surgery.
Nerve repair and regeneration: The Jack Brockhoff
Laboratory is dedicated to researching the mechanisms by which
injured nerves and muscles regenerate.
Blood vessel biology: Successful outcomes for
surgery depend upon a good blood supply to nourish repaired and
transplanted tissue. We are trying to get a better idea of how
blood vessels develop in new tissue, and how to manipulate blood
vessels.
Prostate carcinoma. Very few human prostate cancer
cell lines exist and, in collaboration with Onyvax, Inc., we are
developing new ones. We also have developed the only known model
for osteosclerotic bone metastasis. Characterisation of this model
may provide important leads for the treatment of advanced prostate
cancer.
Competitive
Advantages
The Institute has successfully developed and patented a process
for growing new vascularised tissue in an animal model. Together
with our collaborators, we hope to adapt this new technology to
humans within the next 5 years.
We were also successful in attracting a sizeable contract from Onyvax,
Inc., (UK) for the generation of new prostate cancer cell lines
which may be used in prostate cancer vaccines.
Direct links to clinical practice – the Institute Director
is Chief of Plastic Surgery and 4-5 clinical Fellows train each
year in the clinic and the laboratory.
Potential for expansion with an entire floor ready to be outfitted.
Modern, well-equipped facilities, including large animal facility.
Technology
Proprietary tissue engineering chamber with potential for application
to multiple tissue types.
Corporate
Alliances/Partnerships
Partners
University of Melbourne, Departments of Chemical Engineering and
Surgery
Monash University
CSIRO
Peter MacCallum Cancer Institute
St. Vincent’s Hospital, Melbourne
FibroGen, Inc
Partnering Opportunities
Partnership for the development and commercialisation of specific
tissue engineering outcomes in our chamber (eg. adipose tissue for
defect repair).
Partnering Needs
Commercialisation know-how and infrastructure support.
| Contact Person |
Professor Wayne A. Morrison |
 |
| Job Title |
Director |
| Address |
42 Fitzroy Street |
| City/Suburb |
Fitzroy
Victoria 3065 Australia |
| Email |
morriswa@svhm.org.au |
| Phone |
+61 3 9288 4018 |
| Fax |
+61 3 9416 0926 |
| Website Address |
www.bobim.org |
back
|